Cover Image

Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Yi Zheng, Ziliang Chen, Wenhua Song, Yu Xu, Zhiqiang Zhao, Yihong Sun, Yuanyuan Wang, Xuhong Geng, Jun Zhao, Xiaowei Zhang, Yanmin Xu, Jeffrey Shi Kai Chan, Gary Tse, Guangping Li, Lili Hong, Tong Liu
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Cancer Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis: A systematic review and meta‐analysis
by: Wenhua Song, et al.
Published: (2024)

Immune‐related adverse events in immune checkpoint inhibitor therapy for cancer
by: Katie Liao, et al.
Published: (2025)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024)

Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
by: Hao Xiong, et al.
Published: (2024)

Interpretable machine learning model predicting immune checkpoint inhibitor‐induced hypothyroidism: A retrospective cohort study
by: Su‐Yan Zhu, et al.
Published: (2024)

Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study
by: Mina Fazel, et al.
Published: (2025)

Red blood cell alloimmunization: A new checkpoint inhibitor immune‐related adverse event?
by: Lianne Rotin, et al.
Published: (2025)

Association among major adverse cardiovascular events with immune checkpoint inhibitors: A systematic review and meta‐analysis
by: Haixia Li, et al.
Published: (2024)

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events
by: Kai‐Yang Chen, et al.
Published: (2026)

The association of osteoarthritis with de novo inflammatory arthritis in patients receiving immune checkpoint inhibitors: a retrospective study
by: Shiju Chen, et al.
Published: (2026)

Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
by: Angela E. Alnemri, et al.
Published: (2024)

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
by: Tadashi Nishimura, et al.
Published: (2024)

Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first‐line treatment of unresectable thymic carcinoma: A multicenter retrospective study
by: Baishen Zhang, et al.
Published: (2024)

Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan
by: Masako Shomura, et al.
Published: (2024)

Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer
by: Yiran Rong, et al.
Published: (2024)

Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune‐related adverse events during treatment with immune checkpoint inhibitors
by: Christina Schmitt, et al.
Published: (2025)

A comprehensive atlas of pediatric immune checkpoint inhibitors‐related adverse events: From real‐world pharmacovigilance data to mechanistic insights
by: Anqi Lin, et al.
Published: (2025)

A real‐world data analysis of the impact of clonal hematopoiesis of indeterminate potential on therapeutic efficacy and adverse events of immune checkpoint inhibitors
by: Takamasa Fujita, et al.
Published: (2026)

Dupilumab for immune checkpoint inhibitors‐induced pruritic dermatoses: A retrospective, multicentric study
by: Damien Giacchero, et al.
Published: (2025)

The nutrition‐related adverse events associated with immune checkpoint inhibitor treatment for patients with non‐small cell lung cancer: A systematic review
by: Kate L. Graham, et al.
Published: (2024)

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer
by: Zhuo Cheng, et al.
Published: (2024)

Comparing immunopathogenesis of non‐human immunodeficiency virus immune reconstitution inflammatory syndrome and immune‐related adverse events: A prospective multicenter cohort study
by: Hirohiko Sueki, et al.
Published: (2025)

Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
by: van Eijs, Mick, et al.
Published: (2025)

Clinical relevance of immune checkpoint inhibitors for the analgesic effect of opioids: A retrospective propensity score analysis
by: Takahiro Sumimoto, et al.
Published: (2024)

The effect of common medications on the efficacy of immune checkpoint inhibitors
by: Daria Brinzevich, et al.
Published: (2025)

Orofacial complications from immune checkpoint inhibitors: A retrospective analysis from two academic medical centers
by: Kamal Al‐Eryani, et al.
Published: (2024)

Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
by: Xuemei Zhang, et al.
Published: (2024)

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Gen Lin, et al.
Published: (2024)

Correction to “The effect of common medications on the efficacy of immune checkpoint inhibitors”
Published: (2026)

Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma
by: Xiu Chen, et al.
Published: (2024)

Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?
by: Rocco Simone Flammia, et al.
Published: (2026)

Revisiting the impact of common medications on immune checkpoint inhibitor efficacy
by: Parham Habibzadeh, et al.
Published: (2026)

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
by: Damien Sanogo, et al.
Published: (2025)

Diagnostic guide for immune checkpoint inhibitor‐induced liver injury
by: Takanori Ito, et al.
Published: (2024)

Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
by: Georges Gebrael, et al.
Published: (2024)

A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
by: Yuki Haruta, et al.
Published: (2024)

Correction to “Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 allele”
Published: (2026)

From clinical observations to molecular insights: Decoding immune checkpoint inhibitors‐induced prostatitis
by: Peng Luo, et al.
Published: (2025)

Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives
by: Nozomu Yanaihara, et al.
Published: (2025)

Delayed onset eruptive keratoacanthomas following immune checkpoint inhibitor therapy
by: Megan M. Tran, et al.
Published: (2024)